A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis
He-xiang Zong, Sheng-qian Xu, Jian-xiong Wang, Yi-ran Chu, Ke-ming Chen, Cong Wang, Wan-qiu Tong, Xi-le Wang Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaCorrespondence: Sheng-qian Xu, Department of Rheumatolog...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-08-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-real-world-study-on-the-effect-of-imrecoxib-for-patients-with-axial--peer-reviewed-fulltext-article-DDDT |
| _version_ | 1828355769783812096 |
|---|---|
| author | Zong HX Xu SQ Wang JX Chu YR Chen K Wang C Tong WQ Wang XL |
| author_facet | Zong HX Xu SQ Wang JX Chu YR Chen K Wang C Tong WQ Wang XL |
| author_sort | Zong HX |
| collection | DOAJ |
| description | He-xiang Zong, Sheng-qian Xu, Jian-xiong Wang, Yi-ran Chu, Ke-ming Chen, Cong Wang, Wan-qiu Tong, Xi-le Wang Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaCorrespondence: Sheng-qian Xu, Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, No. 218, Ji-xi Road, Hefei, Anhui, 230022, People’s Republic of China, Tel +86 551 62922261, Fax +86 551 62923040, Email xsqian-1112@163.comPurpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have generally been viewed as first-line therapy for axial spondyloarthritis (axSpA). Imrecoxib is a selective COX-2 inhibitor developed independently in China. At present, only one single-center RCT trial has shown that imrecoxib is equally effective as celecoxib in treating axSpA. Based on real-world data, our study aims to explore the efficiency of imrecoxib and TNF inhibitor (TNFi) combined with imrecoxib in treating axSpA.Patients and Methods: A total of 163 patients with axSpA who had more than two follow-up records in 6 months and treated with imrecoxib/celecoxib/TNFi combined with imrecoxib/TNFi combined with celecoxib from the First Affiliated Hospital of Anhui Medical University SpA Real World Database (AHSpA) were selected for analysis of our study. The linear mixed model was used to compare efficacy indexes before and after treatment and between different groups, adjust baseline measurement value and follow-up time. The Kaplan–Meier survival analysis was used to identify the differences in cumulative clinical remission rates between groups with different treatment at the follow-up period.Results: Results showed that after treatment ASDAScrp was slightly improved in imrecoxib group and celecoxib group within 6 months (p < 0.05). CRP, ESR, BASDAI, ASDAScrp, BASFI, occiput to wall distance and finger floor distance all significantly improved in TNFi combined with imrecoxib group and TNFi combined with celecoxib group within 6 months (all p < 0.05). According to the Kaplan–Meier survival curve and Log rank test analysis, the clinical remission rate was not significantly different between different treatment during 24-month follow-up (all p > 0.05).Conclusion: ASDAScrp improved slightly within 6 months after treatment with imrecoxib, and TNFi combined with imrecoxib significantly improved multiple effect indexes in axSpA patients. The efficacy of imrecoxib and celecoxib in the treatment of axSpA is equivalent. Also, they have the same efficacy after being combined with TNFi.Keywords: axial spondyloarthritis, imrecoxib, celecoxib, TNF inhibitor |
| first_indexed | 2024-04-14T02:48:04Z |
| format | Article |
| id | doaj.art-86396ae00f774c02acf56f3ec4327aab |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-14T02:48:04Z |
| publishDate | 2022-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-86396ae00f774c02acf56f3ec4327aab2022-12-22T02:16:25ZengDove Medical PressDrug Design, Development and Therapy1177-88812022-08-01Volume 162755276577545A Real-World Study on the Effect of Imrecoxib for Patients with Axial SpondyloarthritisZong HXXu SQWang JXChu YRChen KWang CTong WQWang XLHe-xiang Zong, Sheng-qian Xu, Jian-xiong Wang, Yi-ran Chu, Ke-ming Chen, Cong Wang, Wan-qiu Tong, Xi-le Wang Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of ChinaCorrespondence: Sheng-qian Xu, Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, No. 218, Ji-xi Road, Hefei, Anhui, 230022, People’s Republic of China, Tel +86 551 62922261, Fax +86 551 62923040, Email xsqian-1112@163.comPurpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have generally been viewed as first-line therapy for axial spondyloarthritis (axSpA). Imrecoxib is a selective COX-2 inhibitor developed independently in China. At present, only one single-center RCT trial has shown that imrecoxib is equally effective as celecoxib in treating axSpA. Based on real-world data, our study aims to explore the efficiency of imrecoxib and TNF inhibitor (TNFi) combined with imrecoxib in treating axSpA.Patients and Methods: A total of 163 patients with axSpA who had more than two follow-up records in 6 months and treated with imrecoxib/celecoxib/TNFi combined with imrecoxib/TNFi combined with celecoxib from the First Affiliated Hospital of Anhui Medical University SpA Real World Database (AHSpA) were selected for analysis of our study. The linear mixed model was used to compare efficacy indexes before and after treatment and between different groups, adjust baseline measurement value and follow-up time. The Kaplan–Meier survival analysis was used to identify the differences in cumulative clinical remission rates between groups with different treatment at the follow-up period.Results: Results showed that after treatment ASDAScrp was slightly improved in imrecoxib group and celecoxib group within 6 months (p < 0.05). CRP, ESR, BASDAI, ASDAScrp, BASFI, occiput to wall distance and finger floor distance all significantly improved in TNFi combined with imrecoxib group and TNFi combined with celecoxib group within 6 months (all p < 0.05). According to the Kaplan–Meier survival curve and Log rank test analysis, the clinical remission rate was not significantly different between different treatment during 24-month follow-up (all p > 0.05).Conclusion: ASDAScrp improved slightly within 6 months after treatment with imrecoxib, and TNFi combined with imrecoxib significantly improved multiple effect indexes in axSpA patients. The efficacy of imrecoxib and celecoxib in the treatment of axSpA is equivalent. Also, they have the same efficacy after being combined with TNFi.Keywords: axial spondyloarthritis, imrecoxib, celecoxib, TNF inhibitorhttps://www.dovepress.com/a-real-world-study-on-the-effect-of-imrecoxib-for-patients-with-axial--peer-reviewed-fulltext-article-DDDTaxial spondyloarthritisimrecoxibcelecoxibtnf inhibitor |
| spellingShingle | Zong HX Xu SQ Wang JX Chu YR Chen K Wang C Tong WQ Wang XL A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis Drug Design, Development and Therapy axial spondyloarthritis imrecoxib celecoxib tnf inhibitor |
| title | A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis |
| title_full | A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis |
| title_fullStr | A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis |
| title_full_unstemmed | A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis |
| title_short | A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis |
| title_sort | real world study on the effect of imrecoxib for patients with axial spondyloarthritis |
| topic | axial spondyloarthritis imrecoxib celecoxib tnf inhibitor |
| url | https://www.dovepress.com/a-real-world-study-on-the-effect-of-imrecoxib-for-patients-with-axial--peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT zonghx arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT xusq arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT wangjx arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT chuyr arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT chenk arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT wangc arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT tongwq arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT wangxl arealworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT zonghx realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT xusq realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT wangjx realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT chuyr realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT chenk realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT wangc realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT tongwq realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis AT wangxl realworldstudyontheeffectofimrecoxibforpatientswithaxialspondyloarthritis |